<?xml version="1.0" encoding="UTF-8"?>
<fig id="F1" position="float">
 <label>Figure 1</label>
 <caption>
  <p>Vaccine vectors and agents that can be used to elicit and/or enhance the formation of CD8
   <sup>+</sup> T
   <sub>RM</sub> cells in the liver and the vagina. Following intravenous delivery, MVA, Ad serotype 5 (Ad5), ChAd serotype 63 (ChAd63), AAV, NP, and RAS can enter hepatocytes and/or cells surrounding the hepatic tissues (e.g., Kupffer cells) (Nganou-Makamdop et al., 
   <xref rid="B63" ref-type="bibr">2012</xref>; Tay et al., 
   <xref rid="B85" ref-type="bibr">2014</xref>; Gola et al., 
   <xref rid="B32" ref-type="bibr">2018</xref>). Intravenous delivery of these vectors in multi-dose prime/trap (Fernandez-Ruiz et al., 
   <xref rid="B23" ref-type="bibr">2016</xref>; Olsen et al., 
   <xref rid="B65" ref-type="bibr">2018</xref>), prime/target (Gola et al., 
   <xref rid="B32" ref-type="bibr">2018</xref>) or homologous prime/boost (Ishizuka et al., 
   <xref rid="B42" ref-type="bibr">2016</xref>) regimens elicits protection following 
   <italic>P. berghei</italic> sporozoite challenge in mice or controlled 
   <italic>P. falciparum</italic> infections in humans, and elicits intrahepatic CD8
   <sup>+</sup> T
   <sub>RM</sub> cells (Fernandez-Ruiz et al., 
   <xref rid="B23" ref-type="bibr">2016</xref>; Ishizuka et al., 
   <xref rid="B42" ref-type="bibr">2016</xref>; Gola et al., 
   <xref rid="B32" ref-type="bibr">2018</xref>). The prime/trap approaches involve priming CD8
   <sup>+</sup> T cells systemically using antibodies that deliver a peptide antigen to cross-presenting dendritic cells (Fernandez-Ruiz et al., 
   <xref rid="B23" ref-type="bibr">2016</xref>) or using gene gun delivery of DNA encoding the cognate antigen (Olsen et al., 
   <xref rid="B65" ref-type="bibr">2018</xref>). The primed CD8
   <sup>+</sup> T cells are then recruited to the liver and differentiate into T
   <sub>RM</sub> cells (i.e., trapped) following intravenous delivery of AAV (Fernandez-Ruiz et al., 
   <xref rid="B23" ref-type="bibr">2016</xref>) or RAS (Olsen et al., 
   <xref rid="B65" ref-type="bibr">2018</xref>) that enter cells in the liver and express the relevant cognate antigen which are recognized by the primed CD8
   <sup>+</sup> T cells. The prime/target approach is an adaptation of the prime/trap approach and essentially involves priming na√Øve CD8
   <sup>+</sup> T cells with Ad5 or ChAd63 vaccine vector delivered via the intramuscular route and recruiting the primed CD8
   <sup>+</sup> T cells to the liver following intravenous delivery of Ad5, NP, MVA, or ChAd63 vaccine vector (Gola et al., 
   <xref rid="B32" ref-type="bibr">2018</xref>). The same study showed that intravenous delivery was more efficient than intramuscular delivery of vaccine vectors to elicit high numbers of intrahepatic CD8
   <sup>+</sup> T
   <sub>RM</sub> cells and protection against 
   <italic>P. berghei</italic> sporozoite challenge in the prime/target approach (Gola et al., 
   <xref rid="B32" ref-type="bibr">2018</xref>). IL-15 appears to be crucial for activated CD8
   <sup>+</sup> T cells to differentiate into T
   <sub>RM</sub> cells in the liver and inflammatory signals (e.g., CpG and Poly I:C) can enhance the formation of intrahepatic CD8
   <sup>+</sup> T
   <sub>RM</sub> cells 
   <italic>in vivo</italic> (Holz et al., 
   <xref rid="B40" ref-type="bibr">2018</xref>). In the vagina, intravaginal delivery of HPV PsV, and more recently Ad26 and Ad35 have been shown to transduce cervicovaginal epithelial cells and elicit HPV-specific CD8
   <sup>+</sup> T
   <sub>RM</sub> cells in the cervicovaginal mucosa (Cuburu et al., 
   <xref rid="B18" ref-type="bibr">2012</xref>, 
   <xref rid="B20" ref-type="bibr">2015</xref>, 
   <xref rid="B19" ref-type="bibr">2018</xref>). In the absence of a vaccine vector, topical application of CXCL9 and CXCL10 in the vagina can be used to recruit/pull CXCR3
   <sup>+</sup> effector CD8
   <sup>+</sup> T cells into the vagina which subsequently differentiate into cervicovaginal T
   <sub>RM</sub> cells (Shin and Iwasaki, 
   <xref rid="B78" ref-type="bibr">2012</xref>).
  </p>
 </caption>
 <graphic xlink:href="fcimb-09-00091-g0001" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
